Eras-801
Astrocytoma (Excluding Glioblastoma)
Explore 5 assets in Astrocytoma (Excluding Glioblastoma) →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Jonsson Comprehensive Cancer Center
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07089641CT.gov ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Astrocytoma (Excluding Glioblastoma)
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Eras-801 (this asset) | Jonsson Comprehensive Cancer Center | P1 | CC · 43 |
| Niraparib | University of Oklahoma | P2 | CCC |
| Pembrolizumab | Mayo Clinic | P2 | CCC |
| gi-102 | Mayo Clinic | P2 | CCC |
| Fludeoxyglucose | Jonsson Comprehensive Cancer Center | P1 | CC |
Other indications for Eras-801
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| IDH-Wildtype Glioblastoma | — | P1 | CC · 43 |
| Gliosarcoma | — | P1 | CC · 41 |
| Glioblastoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Eras-801 in Astrocytoma (Excluding Glioblastoma). Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/eras-801-astrocytoma-excluding-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →